High Prevalence of Sars-Coronavirus-2 in Patients With Inflammatory Bowel Disease and the Role of Soluble Angiotensin Converting Enzyme2 Publisher



Shahrokh S¹ ; Baradaran Ghavami S¹ ; Asadzadeh Aghdaei H¹ ; Parigi TL^{2, 3} ; Farmani M¹ ; Danese S^{2, 4} ; Ebrahimi Daryani N⁵ ; Vossoughinia H⁶ ; Balaii H¹ ; Alborzi F⁵ ; Khoramjoo SM¹ ; Khanabadi B¹ ; Seyed Salehi A¹ ; Bastani A⁷ Show All Authors
Source: Archives of Physiology and Biochemistry Published:2022

Abstract

Context: Patients with inflammatory bowel disease (IBD) were found to have the higher intestinal expression of Angiotensin-Converting Enzyme2 (ACE2) that could consequently increase susceptibility to COVID-19 infection. Objective: This study reports the outcomes of COVID-19 infection in a large cohort of IBD patients. We compare levels of serum ACE and IFN-α between COVID19 patients with and without IBD. We performed a cross-sectional retrospective multicenter study. Methods: We enrolled patients with IBD screened for SARS-COV-2 in six medical centres in Iran from June to November 2020. The blood samples were drawn to measure COVID-19 IgM and IgG, and serum levels of sACE2, sACE1, and interferon-α, regardless of suspicious symptoms have done the molecular test. Results: A total of 534 IBD patients were included in the study. Of these, 109 (20.0%) cases had detectable IgG and IgM against SARS-CoV-2. sACE2 levels were higher in IBD patients than controls, whereas ACE1and IFN-α levels were similar among groups. © 2022 Informa UK Limited, trading as Taylor & Francis Group.